This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The Cancer Research Institute awarded $28.5 million to scientists at 43 institutions in 8 countries who are advancing lifesaving research in immunology and cancer immunotherapy during its 2021 funding cycle.
This 9th annual Cancer Immunotherapy Month™, CRI aims to help close the information and research gap to better serve the Hispanic community in the United States.
Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month this June.
First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at increased risk of progressing to severe stages of COVID-19
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Meet three promising young scientists changing the face of immuno-oncology: Ryan K. Alexander, Ph.D., of Boston Children’s Hospital; Nelson M. LaMarche, Ph.D., of the Icahn School of Medicine at Mount Sinai; and Christopher B. Medina, Ph.D., of Emory University.
New research, new treatments, and how we’re working toward a future immune to cervical cancer